Faricimab in neovascular age-related macular degeneration: updated week 48 efficacy, safety, and durability in the phase 3 TENAYA and LUCERNE trials

被引：0
|
作者：
London, Nikolas [1 ]
Guymer, Robyn H. [2 ,3 ]
Demetriades, Anna-Maria [4 ]
Ruiz, Carlos Quezada [4 ]
Silverman, David [5 ]
Ives, Jane [5 ]
Basu, Karen [6 ]
Lin, Hugh [4 ]
机构：
[1] Retina Consultants San Diego, San Diego, CA USA
[2] Ctr Eye Res Australia Ltd, Melbourne, Vic, Australia
[3] Royal Victorian Eye & Ear Hosp, Melbourne, Vic, Australia
[4] Genentech Inc, San Francisco, CA 94080 USA
[5] Roche Prod Ltd, Welwyn Garden City, Herts, England
[6] Roche Prod Ireland Ltd, Dublin, Ireland
来源：
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE | 2022年 / 63卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
3120
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Machine Learning to Predict Faricimab Treatment Outcome in Neovascular Age-Related Macular Degeneration
    Kikuchi, Yusuke
    Kawczynski, Michael G.
    Anegondi, Neha
    Neubert, Ales
    Dai, Jian
    Ferrara, Daniela
    Quezada-Ruiz, Carlos
    OPHTHALMOLOGY SCIENCE, 2024, 4 (02):
  • [42] COST-EFFECTIVENESS OF FARICIMAB IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN CANADA
    Buhrer, C.
    Paulo, T.
    Diles, D.
    VALUE IN HEALTH, 2022, 25 (12) : S111 - S112
  • [43] INTRAOCULAR INFLAMMATION FOLLOWING INTRAVITREAL FARICIMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD)
    Punit, Ankita Abhinandan
    Hasan, Hani
    Da Costa, Joanna
    EYE, 2024, 38 : 173 - 173
  • [44] The Short-Term Efficacy and Safety of Faricimab in Refractory Neovascular Age-Related Macular Degeneration: The Real-World Experience in Taiwan
    Chi, Sheng-Chu
    Weng, Chang-Chi
    Chen, Shih-Jen
    Lin, Tai-Chi
    Chou, Yu-Bai
    Hwang, De-Kuang
    OPHTHALMOLOGICA, 2024, 247 (5-6) : 312 - 321
  • [45] The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study-6 month results
    Khanani, Arshad M.
    Aziz, Aamir A.
    Khan, Hannah
    Gupta, Ashwin
    Mojumder, Ohidul
    Saulebayeva, Aigerim
    Abbey, Ashkan M.
    Almeida, David R. P.
    Avery, Robert L.
    Banda, Himanshu K.
    Barakat, Mark R.
    Bhandari, Ramanath
    Chang, Emmanuel Y.
    Haug, Sara J.
    London, Nikolas J. S.
    Mein, Luke
    Sheth, Veeral S.
    Wolfe, Jeremy D.
    Singer, Michael A.
    Danzig, Carl J.
    EYE, 2023, 37 (17) : 3574 - 3581
  • [46] THE REAL-WORLD EFFICACY AND SAFETY OF FARICIMAB IN BOTH TREATMENT NAiVE AND TREATMENT RESISTANT PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
    Lloyd, Aimee
    Abugreen, Salwa
    Kurc, Miguel
    Elbalawi, Mahmoud
    EYE, 2024, 38 : 167 - 167
  • [47] Ocular Pharmacodynamics of Intravitreal Faricimab in Patients With Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema
    Diack, Cheikh
    Avery, Robert L.
    Cheung, Chui Ming Gemmy
    Csaky, Karl G.
    Gibiansky, Leonid
    Jaminion, Felix
    Gibiansky, Ekaterina
    Sickert, Denise
    Stoilov, Ivo
    Cosson, Valerie
    Bogman, Katrijn
    TRANSLATIONAL VISION SCIENCE & TECHNOLOGY, 2024, 13 (11):
  • [48] Aflibercept versus Faricimab in the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Review
    Liberski, Slawomir
    Wichrowska, Malgorzata
    Kociecki, Jaroslaw
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (16)
  • [49] Stereotactic Radiotherapy for Neovascular Age-related Macular Degeneration 52-Week Safety and Efficacy Results of the INTREPID Study
    Jackson, Timothy L.
    Chakravarthy, Usha
    Kaiser, Peter K.
    Slakter, Jason S.
    Jan, Ernest
    Bandello, Francesco
    O'Shaughnessy, Denis
    Gertner, Michael E.
    Danielson, Linda
    Moshfeghi, Darius M.
    OPHTHALMOLOGY, 2013, 120 (09) : 1893 - 1900
  • [50] HAWK and HARRIER Ninety-Six-Week Outcomes from the Phase 3 Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration
    Dugel, Pravin U.
    Singh, Rishi P.
    Koh, Adrian
    Ogura, Yuichiro
    Weissgerber, Georges
    Gedif, Kinfemichael
    Jaffe, Glenn J.
    Tadayoni, Ramin
    Schmidt-Erfurth, Ursula
    Holz, Frank G.
    OPHTHALMOLOGY, 2021, 128 (01) : 89 - 99
12345